Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers
Stock Information for Tonix Pharmaceuticals Holding Corp.
Loading
Please wait while we load your information from QuoteMedia.